With multiple PARPi + ARSI combinations now approved, how are you selecting which combination to use for a patient with BRCA mutated mCRPC?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at University of Minnesota–Masonic Cancer Center
I agree with Dr. @Armstrong. Figure 1 in the attac...
Sign in or Register to read more